MK-3697 a drug, currently being developed by Merck, for the treatment Insomnia. MK-3697 is a potent and selective Orexin receptor type 2 antagonist.

Alpha-carotene is a provitamin A carotenoid present in fruits and vegetables. Higher serum concentrations of α-carotene have been associated with lower risk of cancer and all-cause mortality. It was suggested that genetic variants influence serum concentrations of provitamin A. Recently was found, that α-carotene effectively inhibits Lewis lung carcinoma (LLC) metastasis and suppresses lung metastasis in combination with taxol in LLC-bearing mice, suggesting that Alpha-carotene could be used as an anti-metastatic agent or as an adjuvant for anti-cancer drugs.

PF-514273 is a drug developed by Pfizer, which acts as an extremely selective antagonist for the CB1 receptor, with approximately 10,000x selectivity over the closely related CB2 receptor. Pfizer was developing PF 514273 in phase I clinical studies for the treatment of obesity in the US. However, these studies were discontinued.